iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology
April 24, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Apr 24, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance...
iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
March 27, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Mar 27, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S....
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
March 04, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Mar 4, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the...
Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
February 10, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a...
iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline
January 30, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 30, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biopharmaceutical products, has added a...
iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China
January 21, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 21, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has received a notice...
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
January 15, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 15, 2014) - iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer...